gemcitabine has been researched along with arginyl-glycyl-aspartyl-valine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, W; Mao, Y; Peng, S; Wang, Y; Wu, J; Zhang, X; Zhao, M; Zhao, S | 1 |
| Liu, W; Peng, S; Wang, Y; Wu, J; Zhang, J; Zhang, X; Zhao, M; Zhao, S | 1 |
2 other study(ies) available for gemcitabine and arginyl-glycyl-aspartyl-valine
| Article | Year |
|---|---|
RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine.
Topics: Alanine Transaminase; Animals; Antineoplastic Agents; Aspartate Aminotransferases; Bone Marrow; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Half-Life; Humans; Inhibitory Concentration 50; Male; Mice, Inbred ICR; Nanomedicine; Oligopeptides; Particle Size; Static Electricity | 2019 |
Exploring the action of RGDV-gemcitabine on tumor metastasis, tumor growth and possible action pathway.
Topics: A549 Cells; Animals; Cell Adhesion; Cell Line, Tumor; Cell Movement; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Interleukin-8; Lung Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice, Inbred C57BL; Microscopy, Atomic Force; Oligopeptides; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2020 |